(Health-NewsWire.Net, December 10, 2016 ) The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.
For more information about this report at http://www.reportsweb.com/epilepsy-pipeline-review-h2-2016
Report Scope:
- The report provides a snapshot of the global therapeutic landscape of Epilepsy - The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects - The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Epilepsy
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001394636/sample
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Companies profiles
Adamas Pharmaceuticals, Inc. Advicenne Aeolus Pharmaceuticals, Inc. Aequus Pharmaceuticals Inc. Aestus Therapeutics, Inc. Alexza Pharmaceuticals, Inc. Anavex Life Sciences Corp. Asklepios BioPharmaceutical, Inc. Astellas Pharma Inc. Bial - Portela & Ca, S.A. BioCrea GmbH Biogen Inc Bionomics Limited Biovista Inc. Biscayne Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. D-Pharm Ltd. Eisai Co., Ltd. Glialogix, Inc. Grifols, S.A. GW Pharmaceuticals Plc H. Lundbeck A/S Hyundai Pharmaceutical Co., Ltd. INSYS Therapeutics, Inc. INVENT Pharmaceuticals, Inc. Iproteos S.L. Johnson & Johnson Knopp Biosciences LLC Lead Discovery Center GmbH Lipicard Technologies Limited Lotus Pharmaceutical Co., Ltd. Marathon Pharmaceuticals, LLC Marinus Pharmaceuticals, Inc. Mitochon Pharmaceuticals, Inc. Neurelis, Inc. Neurocrine Biosciences, Inc. Neuron Biopharma SA Novartis AG OPKO Health, Inc. Ovid Therapeutics Inc. Pfizer Inc. PharmatrophiX, Inc. Promius Pharma, LLC PTC Therapeutics, Inc. Retrophin Inc. Sage Therapeutics, Inc. Saniona AB SciFluor Life Sciences, LLC Shire Plc SK Biopharmaceuticals Co., Ltd. Suda Ltd Sumitomo Dainippon Pharma Co., Ltd. Takeda Pharmaceutical Company Limited Trillium Therapeutics Inc. Turing Pharmaceuticals AG UCB S.A. Ultragenyx Pharmaceutical Inc. Upsher-Smith Laboratories, Inc. Vichem Chemie Research Ltd. VistaGen Therapeutics , Inc. Vitality Biopharma Inc Xenon Pharmaceuticals Inc. XERIS Pharmaceuticals, Inc. Zogenix, Inc. Zynerba Pharmaceuticals, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001394636/discount
List of Figures:
Number of Products under Development for Epilepsy, H2 2016 24 Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016 25 Number of Products under Development by Companies, H2 2016 26 Number of Products under Investigation by Universities/Institutes, H2 2016 33 Comparative Analysis by Late Stage Development, H2 2016 35 Comparative Analysis by Clinical Stage Development, H2 2016 36 Comparative Analysis by Early Stage Products, H2 2016 37 Assessment by Monotherapy Products, H2 2016 115 Number of Products by Top 10 Targets, H2 2016 116 Number of Products by Stage and Top 10 Targets, H2 2016 116 Number of Products by Top 10 Mechanism of Actions, H2 2016 122 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 122 Number of Products by Top 10 Routes of Administration, H2 2016 129 Number of Products by Stage and Top 10 Routes of Administration, H2 2016 129 Number of Products by Molecule Types, H2 2016 131 Number of Products by Stage and Molecule Types, H2 2016 131
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|